DK3013964T3 - Sammensætninger til indføring af rna i celler - Google Patents
Sammensætninger til indføring af rna i celler Download PDFInfo
- Publication number
- DK3013964T3 DK3013964T3 DK14742474.1T DK14742474T DK3013964T3 DK 3013964 T3 DK3013964 T3 DK 3013964T3 DK 14742474 T DK14742474 T DK 14742474T DK 3013964 T3 DK3013964 T3 DK 3013964T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- cells
- introducing rna
- rna
- introducing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
- C08G73/0213—Preparatory process
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13174390 | 2013-06-28 | ||
| EP13181380 | 2013-08-22 | ||
| PCT/EP2014/063756 WO2014207231A1 (en) | 2013-06-28 | 2014-06-27 | Compositions for introducing rna into cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3013964T3 true DK3013964T3 (da) | 2020-06-15 |
Family
ID=51224914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14742474.1T DK3013964T3 (da) | 2013-06-28 | 2014-06-27 | Sammensætninger til indføring af rna i celler |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12064484B2 (da) |
| EP (1) | EP3013964B1 (da) |
| JP (1) | JP6609246B2 (da) |
| KR (1) | KR102285326B1 (da) |
| CN (1) | CN105579584B (da) |
| AU (1) | AU2014300980B2 (da) |
| BR (1) | BR112015032225B1 (da) |
| CA (1) | CA2916800C (da) |
| DK (1) | DK3013964T3 (da) |
| EA (1) | EA036400B1 (da) |
| ES (1) | ES2810298T3 (da) |
| WO (1) | WO2014207231A1 (da) |
| ZA (1) | ZA201509111B (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2663360T3 (es) | 2011-06-08 | 2018-04-12 | Translate Bio, Inc. | Lípidos escindibles |
| KR20160121584A (ko) * | 2014-02-26 | 2016-10-19 | 에트리스 게엠베하 | Rna의 위장 투여용 조성물 |
| WO2015173824A1 (en) | 2014-05-14 | 2015-11-19 | Alex Levitzki Management And Holdings Ltd | Improved polyethyleneimine polyethyleneglycol vectors |
| JP2017534649A (ja) * | 2014-11-10 | 2017-11-24 | エスリス ゲーエムベーハーethris GmbH | Bmpをコードするrnaの送達による骨形成誘導 |
| ES2861001T3 (es) | 2015-06-30 | 2021-10-05 | Ethris Gmbh | Polirribonucleótidos que codifican la familia del casete de unión a ATP y formulaciones de los mismos |
| PH12018501168B1 (en) * | 2015-12-01 | 2024-05-17 | Spark Therapeutics Inc | Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use |
| MX2018013919A (es) * | 2016-06-09 | 2019-04-15 | Curevac Ag | Portadores hibridos para cargas de acido nucleico. |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| WO2018127382A1 (en) | 2017-01-03 | 2018-07-12 | Ethris Gmbh | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
| WO2019204451A1 (en) * | 2018-04-17 | 2019-10-24 | Carnegie Mellon University | Enhanced lipid nanoparticle drug delivery using a negatively charged polymer |
| BR112020021054A2 (pt) | 2018-04-25 | 2021-02-17 | Ethris Gmbh | composição, processo para a preparação de uma composição, e, composições sólida e para uso |
| JP7607340B2 (ja) | 2019-02-14 | 2024-12-27 | エスリス ゲーエムベーハー | 繊毛病の治療 |
| CN111249476B (zh) * | 2020-02-19 | 2023-09-26 | 深圳厚存纳米药业有限公司 | 泊洛沙姆和/或泊洛沙胺与脂质组合中性复合物纳米粒 |
| EP4553084A3 (en) | 2020-11-04 | 2025-11-26 | Ethris GmbH | Use of ifn-lambda mrna for treating viral infections |
| WO2022180213A1 (en) | 2021-02-26 | 2022-09-01 | Ethris Gmbh | Formulations for aerosol formation and aerosols for the delivery of nucleic acid |
| US20240277616A1 (en) * | 2021-05-07 | 2024-08-22 | Carnegie Mellon University | Lipid Nanoparticle-Mediated mRNA Delivery to the Pancreas |
| CN113876639B (zh) * | 2021-11-12 | 2023-08-22 | 湖北省麦诗特生物科技有限公司 | 一种含有提高皮肤弹性脂质体的面霜组合物及其制备方法 |
| JP2025529925A (ja) | 2022-08-26 | 2025-09-09 | エスリス ゲーエムベーハー | 安定な脂質またはリピドイドナノ粒子懸濁液 |
| EP4327829A1 (en) | 2022-08-26 | 2024-02-28 | Ethris GmbH | Stabilization of lipid or lipidoid nanoparticle suspensions |
| WO2024121160A1 (en) | 2022-12-05 | 2024-06-13 | Ethris Gmbh | Regulator(s) of energy homeostasis-encoding rna molecule(s) with increased translation efficiency |
| EP4676525A2 (en) | 2023-03-03 | 2026-01-14 | DIOSynVax Ltd | Coronavirus vaccines |
| WO2024240962A1 (en) | 2023-05-25 | 2024-11-28 | Ethris Gmbh | Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof |
| WO2025036956A1 (en) | 2023-08-14 | 2025-02-20 | Ethris Gmbh | Non-systemic mrna administration |
| WO2025045767A1 (en) | 2023-08-25 | 2025-03-06 | Ethris Gmbh | Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| TW202539697A (zh) | 2023-11-15 | 2025-10-16 | 德商拜恩技術股份公司 | 冠狀病毒疫苗 |
| GB202416789D0 (en) | 2023-11-15 | 2025-01-01 | BioNTech SE | SARS-COV-2 immunogenic compositions |
| WO2025255152A1 (en) * | 2024-06-05 | 2025-12-11 | Oregon State University | Polymeric compounds and lipid compositions made using the same |
| WO2026017917A1 (en) | 2024-07-19 | 2026-01-22 | Ethris Gmbh | Rnas with reduced ribosomal frameshift expression products |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US6017700A (en) | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
| AU5345999A (en) | 1998-08-14 | 2000-03-06 | Valentis, Inc. | Protected one-vial formulation for nucleic acid molecules, methods of making thesame by in-line mixing, and related products and methods |
| NZ512244A (en) * | 1998-11-12 | 2003-12-19 | Invitrogen Corp | Polycationic transfection reagents for introducing anions into a cell |
| CA2377207C (en) | 1999-06-25 | 2013-01-08 | Christian Plank | Combinations for introducing nucleic acids into cells |
| WO2002000870A2 (en) | 2000-06-26 | 2002-01-03 | Christian Plank | Method for transfecting cells using a magnetic field |
| EP1409647A4 (en) | 2001-04-30 | 2009-09-09 | Yissum Res Dev Co | COMPOSITE SKELETONS AND METHODS OF USE THEREOF FOR GENERATING COMPLEX TISSUE GRAFT |
| JP4535229B2 (ja) | 2003-05-08 | 2010-09-01 | 国立大学法人 東京大学 | ポリエチレングリコール−ポリカチオンブロック共重合体 |
| CA2590820A1 (en) * | 2004-12-17 | 2006-06-22 | Nitto Denko Corporation | Immobilized degradable cationic polymer for transfecting eukaryotic cells |
| US7829657B2 (en) | 2005-02-10 | 2010-11-09 | The University Of Tokyo | Polycationically charged polymer and the use of the same as a carrier for nucleic acid |
| US20060235459A1 (en) | 2005-04-19 | 2006-10-19 | Das Gladwin S | Balloon catheters and methods for manufacture |
| WO2006138380A2 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| EP4174179B1 (en) | 2005-08-23 | 2025-05-07 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| US20120021042A1 (en) * | 2005-09-15 | 2012-01-26 | Steffen Panzner | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances |
| AU2006325054B2 (en) | 2005-12-15 | 2013-05-02 | Centre National De La Recherche Scientifique (Cnrs) | Cationic oligonucleotides, automated methods for preparing same and their uses |
| AU2009311667B2 (en) * | 2008-11-07 | 2016-04-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| WO2010065660A2 (en) * | 2008-12-02 | 2010-06-10 | University Of Utah Research Foundation | Biodegradable polydisulfide amines for gene delivery |
| CN102695525B (zh) | 2009-07-31 | 2016-01-20 | 埃泽瑞斯公司 | 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna |
| WO2011154331A1 (en) | 2010-06-10 | 2011-12-15 | F. Hoffmann-La Roche Ag | Polymers for delivery of nucleic acids |
| US9168230B2 (en) | 2011-05-26 | 2015-10-27 | University Of South Carolina | Tetrary gene delivery system for gene therapy and methods of its use |
| DE102011114986A1 (de) | 2011-09-28 | 2013-03-28 | Ethris Gmbh | Sprühsystem |
| HUE057725T2 (hu) | 2011-10-03 | 2022-06-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása |
| WO2014066811A1 (en) | 2012-10-25 | 2014-05-01 | The Johns Hopkins University | Bioreducible poly (b-amino ester)s for sirna delivery |
| HRP20220717T1 (hr) * | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
| CA2884870C (en) * | 2012-08-13 | 2022-03-29 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
-
2014
- 2014-06-27 US US14/901,467 patent/US12064484B2/en active Active
- 2014-06-27 JP JP2016522546A patent/JP6609246B2/ja active Active
- 2014-06-27 KR KR1020167001398A patent/KR102285326B1/ko active Active
- 2014-06-27 CA CA2916800A patent/CA2916800C/en active Active
- 2014-06-27 EA EA201600044A patent/EA036400B1/ru not_active IP Right Cessation
- 2014-06-27 BR BR112015032225-5A patent/BR112015032225B1/pt active IP Right Grant
- 2014-06-27 DK DK14742474.1T patent/DK3013964T3/da active
- 2014-06-27 EP EP14742474.1A patent/EP3013964B1/en active Active
- 2014-06-27 ES ES14742474T patent/ES2810298T3/es active Active
- 2014-06-27 CN CN201480048096.7A patent/CN105579584B/zh active Active
- 2014-06-27 AU AU2014300980A patent/AU2014300980B2/en active Active
- 2014-06-27 WO PCT/EP2014/063756 patent/WO2014207231A1/en not_active Ceased
-
2015
- 2015-12-14 ZA ZA2015/09111A patent/ZA201509111B/en unknown
-
2024
- 2024-08-08 US US18/798,342 patent/US20250041443A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3013964A1 (en) | 2016-05-04 |
| CN105579584A (zh) | 2016-05-11 |
| CA2916800C (en) | 2022-10-25 |
| BR112015032225A2 (pt) | 2017-07-25 |
| EA036400B1 (ru) | 2020-11-06 |
| JP6609246B2 (ja) | 2019-11-20 |
| CN105579584B (zh) | 2020-08-28 |
| KR102285326B1 (ko) | 2021-08-04 |
| CA2916800A1 (en) | 2014-12-31 |
| BR112015032225B1 (pt) | 2022-05-17 |
| ES2810298T3 (es) | 2021-03-08 |
| AU2014300980A1 (en) | 2016-01-07 |
| EP3013964B1 (en) | 2020-05-06 |
| WO2014207231A1 (en) | 2014-12-31 |
| US12064484B2 (en) | 2024-08-20 |
| US20250041443A1 (en) | 2025-02-06 |
| KR20160040524A (ko) | 2016-04-14 |
| EA201600044A1 (ru) | 2016-06-30 |
| US20170021036A1 (en) | 2017-01-26 |
| AU2014300980B2 (en) | 2020-03-05 |
| ZA201509111B (en) | 2021-03-31 |
| JP2016524898A (ja) | 2016-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3013964T3 (da) | Sammensætninger til indføring af rna i celler | |
| DK2978419T3 (da) | Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf | |
| IL245573B (en) | Cell | |
| PL2884999T3 (pl) | Sposób i kompozycje do immunoterapii komórkowej | |
| EP3488847C0 (en) | SEMIFLUORINATED ALKANE COMPOSITIONS | |
| BR112015027279A8 (pt) | métodos e composições para acentuar células t reguladoras cd4+ | |
| DK2953634T3 (da) | Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler | |
| DK3079658T3 (da) | Kammer til indkapsling af secernerende celler | |
| DK3042411T3 (da) | Metalunderstøttet fastoxidbrændselscelle | |
| PL3017520T3 (pl) | Zespół ogniw słonecznych | |
| DK2941483T3 (da) | Fremgangsmåde til at opnå immunstimulerende dendritriske celler | |
| FI11677U1 (fi) | Uusiutuva hiilivetykoostumus | |
| DK2686434T3 (da) | Fremgangsmåde til reduktion af viskositet i saccharificeringsproces | |
| LT3702351T (lt) | Kompozicijos, apimančios mek inhibitorių | |
| DK3242903T3 (da) | Sammensætninger til at indføre nukleinsyre i celler | |
| DK2941484T3 (da) | Fremgangsmåde til at opnå immunsuppressive dendritriske celler | |
| DK3421470T3 (da) | Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form | |
| EP3011599C0 (en) | PHOTOVOLTAIC DEVICES | |
| DK3394248T3 (da) | Dendritisk cellesammensætning | |
| EP3719852C0 (en) | SOLAR CELL | |
| FI11676U1 (fi) | Uusiutuva hiilivetykoostumus | |
| DK2970843T3 (da) | Fremgangsmåder til frembringelse af cellebank med høj densitet | |
| DK3003285T3 (en) | Fast farmaceutisk dosisform til frigivelse af mindst to aktive farmaceutiske ingredienser i mundhulen | |
| EP3066193C0 (en) | CELL CULTURE PROCESS | |
| KR102535561B9 (ko) | 태양 전지를 이용한 구조물 |